Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Aurobindo Pharma, Jubilant Rated New ‘Buy’ at Goldman Sachs

Oct. 20 (Bloomberg) -- Aurobindo Pharma Ltd. and Jubilant Life Sciences Ltd. were rated “buy” in new coverage at Goldman Sachs Group Inc., which cited an improving revenue outlook, greater capacity utilization and easing balance sheet concerns.

The brokerage has a share-price estimate of 1,545 rupees for Aurobindo Pharma and a forecast of 408 rupees for Jubilant Life Sciences, according to a report by analysts including Balaji V. Prasad.

Link to Company News:{ARBP IN <Equity> CN <GO>} Link to Company News:{JOL IN <Equity> CN <GO>}

To contact the editor responsible for this story: Shiyin Chen at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.